Compare BAER & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAER | RANI |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 235 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 106.9M |
| IPO Year | N/A | 2021 |
| Metric | BAER | RANI |
|---|---|---|
| Price | $1.94 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $7.50 |
| AVG Volume (30 Days) | 455.5K | ★ 634.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | $16.47 | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $1.47 | $0.39 |
| 52 Week High | $3.44 | $3.87 |
| Indicator | BAER | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 35.15 |
| Support Level | $1.58 | $0.45 |
| Resistance Level | $1.97 | $0.83 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.36 | 20.70 |
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Its revenues is derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation services. The company's portfolio is organized across three offerings namely : Fire Suppression; Aerial Surveillance; and Maintenance, Repair and Overhaul (MRO). The company operates as a single operating segment. Its revenues are derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation service. Geographically, it operates in Spain and United States.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.